peeker finance you have business and its is important to know about stocks, markets, currency and the financial matters you need to know about will be at peekerfinance.com
Related Articles
Johnson & Johnson has agreed to acquire Actelion Ltd. for $30 billion, in an unusual deal that will also spin out the Swiss biotech company’s drug-discovery operations.
The deal, the largest in J&J’s history and announced by both companies Thursday, ends weeks of seesaw negotiations.
J&J initially abandoned talks, only to resume them about a week later after the companies entered into exclusive negotiations.
as declared in
Johnson & Johnson Bolsters Drug Roster With $30 Billion Actelion Deal
*/
Johnson & Johnson would pay for the transaction with cash it holds outside the United States.
“We believe this transaction offers compelling value to both Johnson & Johnson and Actelion shareholders,” Alex Gorsky, the chairman and chief executive of Johnson & Johnson, said in a news release.
Jean-Paul Clozel, the Actelion chief executive, would serve as the spinoff’s chief executive, and Jean-Pierre Garnier, Actelion’s chairman, would be its chairman.
It is conditioned on Actelion shareholders agreeing to the spinoff and to sell at least 67 percent of their shares to Johnson & Johnson.
Johnson & Johnson would initially own 16 percent of the new research and development company, with the right to acquire an additional 16 percent.
as declared in
*/
Johnson & Johnson shareholders are also expected to realize additional value from the Johnson & Johnson convertible ownership interest in R&D NewCo.
Value-enhancing transaction for Johnson & Johnson shareholders : The transaction is expected to be immediately accretive to Johnson & Johnson earnings per share and accelerate Johnson & Johnson revenue and earnings growth rates, while enhancing long-term growth and value creation of the Janssen Pharmaceuticals business.
About Johnson & JohnsonCaring for the world, one person at a time, inspires and unites the people of Johnson & Johnson.
About the Janssen Pharmaceutical Companies of Johnson & JohnsonAt the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease.
Johnson & Johnson embraces research and science – bringing innovative ideas, products and services to advance the health and well-being of people.
collected by :John Locas
read more
visit us
